Gastric Cancer

, Volume 5, Supplement 1, pp 31–34 | Cite as

Docetaxel in combination for advanced gastric cancer

  • Jaffer A. Ajani


Docetaxel is considered to be active in untreated and previously treated patients with gastric carcinoma. In a multinational phase II trial (TAX 325), 158 untreated patients with advanced gastric cancer (99% without prior chemotherapy) were randomized to receive, every 3 weeks, either docetaxel 85 mg/m2 plus cisplatin 75 mg/m2 (TC) or docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, plus a 5-day continuous infusion of 750 mg/m2 5-fluorouracil (FU; TCF). By intent-to-treat analysis, patients receiving TCF had a significantly higher response rate and longer time to progression. Overall survival in the two arms was not significantly different. Toxicity (particularly gastrointestinal toxicity) was greater with the TCF combination than in the TC arm, and there was a greater need for dose reduction. However, adverse events in both arms were manageable and there were no deaths associated with either regimen. Following these findings, a phase III trial comparing a control arm of cisplatin plus 5-FU against an experimental arm consisting of the TAX 325 phase II docetaxel/cisplatin/5-FU regimen is now in progress.


Public Health Carcinoma Adverse Event Docetaxel Dose Reduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Karpeh, MS, Kelsen, DP, Tepper, JE 1993Cancer of the stomachDeVita, VTHellman, SRosenberg, SA eds. Cancer: principles and practice of oncologyLippincott, Williams and WilkinsPhiladelphia1092122Google Scholar
  2. 2.
    Garcia, AA, Leichman, CG, Lenz, HJ, Baranda, J, Lujan, R, Casagrande, Y,  et al. 2001Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomachJpn J Clin Oncol312758PubMedCrossRefGoogle Scholar
  3. 3.
    Ajani, JA, Ilson, DH, Kelsen, DP 1996Paclitaxel in the treatment of patients with upper gastrointestinal carcinomasSemin Oncol23558PubMedGoogle Scholar
  4. 4.
    Futatsuki, K, Wakui, A, Nakao, I, Sakata, Y, Kambe, M, Shimada, Y,  et al. 1994Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study GroupGan To Kagaku Ryoho (Jpn J Cancer Chemother)2110338Google Scholar
  5. 5.
    Armand, JP, Cunningham, D, van Cutsem, E, Misset, JL, Kohne, CH 1999Clinical advances with topoisomerase I inhibitors in gastrointestinal malignanciesAnticancer Drugs10S512PubMedGoogle Scholar
  6. 6.
    Kohne, CH, Wils, JA, Wilke, HJ 2000Developments in the treatment of gastric cancer in EuropeOncology (Huntingt)14225Google Scholar
  7. 7.
    Tahara, M, Ohtsu, A 2000Latest progress in chemotherapy for advanced gastric cancerGan To Kagaku Ryoho (Jpn J Cancer Chemother)27204858Google Scholar
  8. 8.
    Bokemeyer, C, Hartmann, JT, Lampe, CS, Clemens, MR, Quietzsch, D, Forkmann, L,  et al. 1997Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancerSemin Oncol24S19-96S19-100Google Scholar
  9. 9.
    Kim, YH, Shin, SW, Kim, BS, Kim, JH, Kim, JG, Mok, YJ,  et al. 1999Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinomaCancer85295301PubMedGoogle Scholar
  10. 10.
    Murad, AM, Petroianu, A, Guimaraes, RC, Aragao, BC, Cabral, LO, Scalabrini-Neco, AO 1999Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimenAm J Clin Oncol225806PubMedCrossRefGoogle Scholar
  11. 11.
    Shirao, K, Shimada, Y, Kondo, H, Saito, D, Yamao, T, Ono, H,  et al. 1997Phase I–II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancerJ Clin Oncol159217PubMedGoogle Scholar
  12. 12.
    Sato, A, Kurihara, M, Matsukawa, M, Shimada, K, Yamazaki, T, Nakamachi, M,  et al. 2001Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancerCancer Chemother Pharmacol473804PubMedCrossRefGoogle Scholar
  13. 13.
    Ajani, JA, Baker, J, Pisters, PW, Ho, L, Feig, B, Mansfield, PF 2001Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinomaOncology (Huntingt)15524Google Scholar
  14. 14.
    Pozzo, C, Bugat, R, Peschel, C, Gorbunova, V, Valvere, V, Zaluski, J,  et al. 2001Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma: final results of a randomised phase II study (abstract)Proc Am Soc Clin Oncol20531Google Scholar
  15. 15.
    Grau, JJ, Martín, M, Gascón, P, Pera, M, Graupera, J, Balcells, M,  et al. 2001Phase II study of irinotecan (CPT-11) and mitomycin c (MMC) combination in patients with advanced gastric cancer (ENG). Preliminary results (abstract)Proc Am Soc Clin Oncol202284Google Scholar
  16. 16.
    Findlay, PN, Ackland, S, Gebski, V, Yuen, J, Boyer, M, Walpole, E,  et al. 2001Phase II study of irinotecan, leucovorin and 5FU (ILF) in advanced gastric cancer (abstract)Proc Am Soc Clin Oncol20655Google Scholar
  17. 17.
    Sulkes, A, Smyth, J, Sessa, C, Dirix, LY, Vermorken, JB, Kaye, S,  et al. 1994Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials GroupBr J Cancer703803PubMedGoogle Scholar
  18. 18.
    Einzig, AI, Neuberg, D, Remick, SC, Karp, DD, O'Dwyer, PJ, Stewart, JA,  et al. 1996Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293Med Oncol138793PubMedGoogle Scholar
  19. 19.
    Mavroudis, D, Kourousis, C, Androulakis, N, Kalbakis, K, Agelaki, S, Kakolyris, S,  et al. 2000Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trialAm J Clin Oncol233414PubMedCrossRefGoogle Scholar
  20. 20.
    Vanhoefer, U, Wilke, H, Harstrick, A, Kalbakis, K, Agelaki, S, Kakolyris, S,  et al. 1999Phase II study of docetaxel as second line chemotherapy (CT) in metastatic gastric cancer (abstract)Proc Am Soc Clin Oncol181163Google Scholar
  21. 21.
    Taguchi, T, Sakata, Y, Kanamaru, R, Fazio, N, Aapro, MS, Pagani, O,  et al. 1998Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)Gan To Kagaku Ryoho (Jpn J Cancer Chemother)25191524Google Scholar
  22. 22.
    Roth, AD, Maibach, R, Martinelli, G, Fazio, N, Aapro, MS, Pagani, O,  et al. 2000Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)Ann Oncol113016PubMedCrossRefGoogle Scholar
  23. 23.
    Ridwelski, K, Gebauer, T, Fahlke, J, Kroning, H, Kettner, E, Meyer, F,  et al. 2001Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancerAnn Oncol124751PubMedCrossRefGoogle Scholar
  24. 24.
    Ajani, JA, Fodor, M, Van Cutsem, E, Tjulandin, S, Moiseyenko, V, Cabral, F,  et al. 2000Multinational randomized phase II trial of docetaxel (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC) (abstract)Proc Am Soc Clin Oncol19957Google Scholar

Copyright information

© International and Japanese Gastric Cancer Associations 2002

Authors and Affiliations

  • Jaffer A. Ajani
    • 1
  1. 1.University of Texas MD Anderson Cancer CenterTexasUSA

Personalised recommendations